Summary
Advanced cancer, because of its accompanying tumor burden, complex adverse host effects, and cellular heterogeneity, will prove much more difficult to control successfully than grave infectious diseases such as tuberculosis. This will likely be so, even when moderately successful chemotherapy is or will be available. Nevertheless, prospects for improving current results are present through application of chemo- therapy alone or in combination with other modalities. Important developments include not only the availability of an increasing number of effective drugs, but also a better understanding of drug pharmacology, prediction of tumor cell cytotoxicity, locoregional drug delivery, exploitation of interactions with other forms of local therapy, and delineation of immunologic factors in tumor control. The single, most likely contribution to a curative approach to cancer, however, is likely to emerge from the application of aggressive systemic treatment in the circumstances of minimal residual disease. This topic is covered elsewhere.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Valagussa P, Rossi A, Zucali R, Tancini G, Bajetta E, Brambilla C, DeLena M, DiFronzo G, Banfi A, Rilke F, Veronesi U (1978) Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol 5:450
Brereton HD, Kent CH, Johnson RE (1979) Chemotherapy and radiation therapy for small cell carcinoma of the lung: A remedy for past therapeutic failure in lung cancer. In: Muggia FM, Rozencweig M (eds) Lung cancer: Progress in therapeutic research. Raven, New York, pp 575–586
D’Angio GJ, Evans AE, Breslow N, Beckwith B, Bishop H, Feigl P, Goodwin W, Leape LL, Sinks LF, Sutow W, Tefft M, Wolff J (1976) The treatment of Wilms’ tumor: Results of the National Wilms’ Tumor Study. Cancer 38:633–645
DeVita VT, Oliverio VT, Muggia FM, Wiernik PW, Ziegler J, Goldin A, Rubin D, Henney J, Schepartz S (1979) The drug development and clinical trials programs of the Division of Cancer Treatment, National Cancer Institute. Cancer Clin Trials 2:195–216
Griffiths CT, Parker CM, Fuller AF Jr (1979) Role of cytoreductive surgical treatment in management of advanced ovarian cancer. Cancer Treat Rep 63:235–240
Muggia F, Catane R, Lee Y, Rozencweig M (1980) Factors responsible for therapeutic success in osteosarcoma: A critical analysis of adjuvant trial results. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer, part II. North-Holland, New York, pp 383–390
Muggia FM, Jacobs EM (1979) Adjuvant chemotherapy of testicular carcinoma: The need for evaluation of curative strategies. In: Bonadonna G, Mathé G, Salmon SE (eds) Recent Results in Cancer Research, vol 68. Springer, Berlin Heidelberg New York
Muggia FM, Rozencweig M, Chiuten DF, Jensen-Akula MS, Charles LM, Kubota T, Bono VH Jr (1980) Phase II trials: Use of a clinical tumor panel and overview of current resources and studies. Cancer Treat Rep 64:1–9
Nervi C, Arcangeli G, Concolino F, Cortese M (1980) Prolonged survival with postirradiation adjuvant chemotherapy in stage IV breast cancer. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer, part II. North-Holland, New York, pp 311–317
Rozencweig M, DeSloover C, Von Hoff DD, Tagnon H, Muggia FM (1979) Introduction: Anthracycline derivatives in new drug development programs. Cancer Treat Rep 63:807–809
Rozencweig M, Von Hoff DD, Staquet MJ, Guarino AG, Penta JS, Muggia FM (1979) Predictive value of animal toxicology with anticancer agents prior to early clinical trials. Clin Res 27:391A
Salmon SE, Hamburger AW, Soehlen B, Durie BGM, Alberts DS, Moon TS (1978) Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327
Speyer JL, Collins JM, Dedrick RL, Brennan MF, Londer H, DeVita VT Jr, Myers CE (1979) Phase I and pharmacological studies of intraperitoneal (I.P.) 5-fluorouracil (5-FU). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:352
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Muggia, F.M., Henney, J., DeVita, V. (1980). General Progress in Clinical Chemotherapy of Advanced Disease. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-81488-4_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81490-7
Online ISBN: 978-3-642-81488-4
eBook Packages: Springer Book Archive